KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $35.6 million.

  • Biomarin Pharmaceutical's Net Cash Flow rose 112.10% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $575.9 million, marking a year-over-year increase of 630.07%. This contributed to the annual value of $182.9 million for FY2024, which is 524.44% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Net Cash Flow is $35.6 million, which was down 78.85% from $168.1 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Net Cash Flow registered a high of $264.9 million during Q4 2024, and its lowest value of -$293.8 million during Q3 2024.
  • For the 3-year period, Biomarin Pharmaceutical's Net Cash Flow averaged around $47.6 million, with its median value being $89.1 million (2023).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Net Cash Flow crashed by 947.55% in 2023, and later surged by 1,167.58% in 2025.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Net Cash Flow stood at -$29.8 million in 2021, then dropped by 24.16% to -$37.1 million in 2022, then increased by 28.11% to -$26.6 million in 2023, then soared by 1,094.33% to $264.9 million in 2024, then spiked by 112.10% to $35.6 million in 2025.
  • Its Net Cash Flow was $35.6 million in Q3 2025, compared to $168.1 million in Q2 2025 and $107.4 million in Q1 2025.